Walvax Biotechnology Co., Ltd. (SHE:300142)

China flag China · Delayed Price · Currency is CNY
11.50
-0.06 (-0.52%)
Mar 28, 2025, 2:45 PM CST
-25.57%
Market Cap 18.31B
Revenue (ttm) 3.10B
Net Income (ttm) 122.37M
Shares Out 1.60B
EPS (ttm) 0.08
PE Ratio 149.65
Forward PE 67.35
Dividend 0.01 (0.09%)
Ex-Dividend Date May 30, 2024
Volume 19,811,378
Average Volume 24,303,985
Open 11.64
Previous Close 11.56
Day's Range 11.48 - 11.75
52-Week Range 9.78 - 18.98
Beta 0.66
RSI 42.14
Earnings Date Mar 22, 2025

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococc... [Read more]

Sector Healthcare
Founded 2001
Employees 2,388
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300142
Full Company Profile

Financial Performance

In 2023, Walvax Biotechnology's revenue was 4.11 billion, a decrease of -19.12% compared to the previous year's 5.09 billion. Earnings were 419.39 million, a decrease of -42.44%.

Financial Statements

News

There is no news available yet.